Collaborations, Licensing and Other Arrangements - Additional Information (Detail) - USD ($)		1 Months Ended		12 Months Ended
	Oct. 31, 2018	Dec. 31, 2023	May 31, 2018	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022	Feb. 28, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments				$ 752,000	$ 924,000	$ 1,088,000
Deferred revenue		$ 78,879,000		63,567,000	78,879,000	39,417,000
Deferred revenue - current		9,085,000		12,407,000	9,085,000
Deferred revenue - non-current		$ 69,794,000		51,160,000	69,794,000
Total revenue from UT				285,504,000	198,962,000	99,770,000
Amphastar
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Performance obligation transaction price				2,500,000
Performance obligation transaction price recognized				500,000
Performance obligation transaction price yet to recognize				2,000,000
Next-Gen R&D Services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue				2,900,000
Collaborations and services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT				100,840,000	52,954,000	27,924,000
AFREZZA product sales
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT				82,329,000	74,029,000	56,247,000
United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT				201,428,000	124,786,000	42,851,000
Thirona Bio, Inc.
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Minimum amount to expended							$ 1,100,000
Funded amount				$ 1,100,000
Collaboration and License Agreement | United Therapeutics Corporation
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Royalty percentage	10.00%
Royalty future net sales percentage		1.00%
Royalty retaining percentage		9.00%
License agreement description				There have been various amendments to the UT License Agreement and the CSA since inception. As amended, the term of the CSA continues until December 31, 2031 (unless earlier terminated) and is thereafter renewed automatically for additional, successive two-year terms unless (i) UT provides notice to the Company at least 24 months in advance of such renewal that UT does not wish to renew the CSA or (ii) the Company provides notice to UT at least 48 months in advance of such renewal that the Company does not wish to renew the CSA
Deferred revenue		$ 77,500,000		$ 62,400,000	77,500,000
Deferred revenue - current		8,900,000		12,300,000	8,900,000
Deferred revenue - non-current		68,600,000		50,100,000	68,600,000
Commercial Supply Agreement | United Therapeutics Corporation | Collaborations and services
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT				96,228,000	52,025,000	24,826,000
Co-Promotion Agreement | Collaborations and services | Amphastar
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT				500,000
Supply and Distribution Agreement | AFREZZA product sales | Biomm
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT				0	0	0
License and Distribution Agreement | Cipla Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Milestone payments				1,100,000
Deferred revenue		1,400,000		1,200,000	1,400,000
Deferred revenue - current		200,000		100,000	200,000
Deferred revenue - non-current		$ 1,200,000		1,100,000	$ 1,200,000
Marketing and distribution agreement date			2018-05
License and Distribution Agreement | Collaborations and services | Cipla Ltd
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Total revenue from UT				$ 1,247,000		$ 147,000
License and Distribution Agreement | Nonrefundable Licensing Fee
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Deferred revenue			$ 2,200,000